Calcium channel blockers (CCB) were found to be associated with improved overall survival in pancreatic cancer patients undergoing neoadjuvant chemotherapy and resection. A retrospective study of 6,223 patients showed that CCB prescription was specifically beneficial in the subgroup receiving neoadjuvant chemotherapy, reflecting the chemosensitizing effect observed in laboratory studies. These findings suggest that patients receiving neoadjuvant chemotherapy could be a target population for prospective clinical trials of CCB in pancreatic cancer. This repurposing approach holds promise for more efficient, cost-effective, and safe oncological treatments.
Journal Article by Fong ZV, Severs G (…) Tingle S et 3 al. in HPB (Oxford)
Copyright © 2023 International Hepato-Pancreato-Biliary Association Inc. Published by Elsevier Ltd. All rights reserved.